LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

Hm Earl ,M Debled,V Georgoulias,P.F Conte,D Cameron,Andrew M Wardley ,Céline Faure-Mercier ,David L Cox ,Gilles Romieu ,Heikki Joensuu ,Henrik Lindman ,James Abraham ,Judith Fraser ,Julie Dunn ,Louise Hiller ,Roberto D’amico ,Teppo Huttunen ,Valentina Guarneri ,D W Miles ,Xavier Pivot

doi:10.1016/j.annonc.2021.08.2083

LBA11 Individual patient data meta-analysis of 5 non-inferiority RCTs of reduced duration single agent adjuvant trastuzumab in the treatment of HER2 positive early breast cancer

Hm Earl , M Debled + Show 18 more

Open Access

https://doi.org/10.1016/j.annonc.2021.08.2083

Copy DOI

Journal: Annals of oncology : official journal of the European Society for Medical Oncology	Publication Date: Sep 1, 2021
Citations: 17	License type: publisher-specific-oa

Affiliation: Institut Bergonié, University Hospital of Heraklion, Northwood

#HER-2 Positive Early Breast Cancer #Positive Early Breast Cancer Patients + Show 8 more

Abstract
Full-Text PDF
Similar Papers

Abstract

We planned an individual patient data (IPD) meta-analysis of non-inferiority (NI) RCTs to determine if a duration of less than the standard of 12 months (m) of adjuvant trastuzumab is non-inferior for treatment outcomes in HER-2 positive early breast cancer patients.

Full Text